Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Accuray Inc (ARAY)

Accuray Inc (ARAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Accuray: Fiscal Q2 Earnings Snapshot AP - Wed Feb 4, 3:44PM CST

Accuray: Fiscal Q2 Earnings Snapshot

ARAY : 0.5523 (+3.33%)
Accuray Reports Fiscal 2026 Second Quarter Financial Results PR Newswire - Wed Feb 4, 3:05PM CST

MADISON, Wis. , Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2025.

ARAY : 0.5523 (+3.33%)
Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026 PR Newswire - Wed Jan 21, 3:05PM CST

MADISON, Wis. , Jan. 21, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2026, ended December 31, 2025, during a conference...

ARAY : 0.5523 (+3.33%)
Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth PR Newswire - Mon Dec 15, 2025

MADISON, Wis. , Dec. 15, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced the first phase of its comprehensive strategic, operational, and organizational transformation plan....

ARAY : 0.5523 (+3.33%)
Accuray: Fiscal Q1 Earnings Snapshot AP - Wed Nov 5, 2025

Accuray: Fiscal Q1 Earnings Snapshot

ARAY : 0.5523 (+3.33%)
Accuray Reports Fiscal 2026 First Quarter Financial Results PR Newswire - Wed Nov 5, 2025

MADISON, Wis. , Nov. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2025.

ARAY : 0.5523 (+3.33%)
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules PR Newswire - Fri Oct 31, 2025

MADISON, Wis. , Oct. 31, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Stephen La Neve, the company's new...

ARAY : 0.5523 (+3.33%)
Accuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025 PR Newswire - Tue Oct 28, 2025

MADISON, Wis. , Oct. 28, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2026, ended September 30, 2025, during a conference...

ARAY : 0.5523 (+3.33%)
Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth PR Newswire - Mon Oct 20, 2025

Industry Veteran Steve La Neve Named Chief Executive Officer  Suzanne Winter to Retire as President and CEO Company Appoints Steven F. Mayer as Transformation Board Sponsor...

ARAY : 0.5523 (+3.33%)
Biomarker-Driven Therapies And AI Technologies Transform $312B Precision Oncology Market BayStreet.ca - Fri Oct 17, 2025

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Biomarker-driven approaches enhance the likelihood of identifying optimal patient populations and streamline...

CORT : 34.24 (-14.01%)
ARAY : 0.5523 (+3.33%)
KURA : 8.58 (+1.06%)
GTBP : 0.4561 (-6.61%)
TNGX : 12.35 (-0.48%)

Barchart Exclusives

Nvidia Dumped Recursion Pharmaceuticals Stock. Should You? Barchart - Thu Feb 19, 3:47PM CST
Nvidia sold its position in Recursion Pharmaceuticals, while others keep a measured outlook. Does this divergence signal risk or opportunity? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot